Table 2. Active or recruiting trials of... | American Society of Hematology

Table 2.

Active or recruiting trials of maintenance therapy after allogeneic HCT listed onclinicaltrials.gov

	ClinicalTrials.gov identifier	Status	Disease	Maintenance agent	Phase study
FLT3⁺ disease	#NCT02997202	Active, not recruiting	FLT3⁺ AML	Gilteritinib	3
FLT3⁺ disease	#NCT02400255	Active, not recruiting	FLT3⁺ AML	Crenolanib	2
IDH mutated disease	#NCT03515512	Active, not recruiting	AML, MDS, CMML	Enasidenib	1
	#NCT03728335	Recruiting	AML	Enasidenib	1
	#NCT04522895	Recruiting	AML, MDS, CMML	Enasidenib	2
	#NCT04522895	Recruiting	AML, MDS	Enasidenib, ivosidenib	3
	#NCT03564821	Recruiting	AML, MDS, CMML	Ivosidenib	1
Ph⁺ disease	#NCT05024357	Recruiting	Ph⁺ ALL	Dasatinib	NA
HMA-based approaches	#NCT04173533	Recruiting	AML, MDS	Azacitidine	3
	#NCT01995578	Active, not recruiting	AML, MDS	Azacitidine	2
	#NCT03931291	Active, not recruiting	AML, MDS	Azacitidine, APR-246	2
	#NCT02124174	Recruiting	AML, MDS	Azacitidine, valproic acid	2
	#NCT03613532	Recruiting	AML, MDS	Azacitidine, venetoclax	1
	#NCT04161885	Recruiting	AML	Azacitidine, venetoclax	3
	#NCT04980404	Recruiting	MDS, CMML	Decitabine/cedazuridine	1
Additional targeted or disease-specific approaches	#NCT04674345	Recruiting	Acute leukemia	Sorafenib	2
	#NCT04168502	Recruiting	AML	Glasdegib	3
	#NCT03932643	Recruiting	AML, MDS	ONC 201	1
	#NCT03286530	Recruiting	AML, MDS	Ruxolitinib	2
	#NCT03267186	Active, not recruiting	Acute leukemia, CML	Ibrutinib	2
	#NCT04326764	Recruiting	AML, MDS	Panobinostat	3
	#NCT01433965	Active, not recruiting	AML, MDS	Lenalidomide	1
	#NCT02807883	Active, not recruiting	ALL	Blinatumomab	2
	#NCT03114865	Recruiting	B-cell ALL or NHL	Blinatumomab	1B/2
	#NCT03151057	Active, not recruiting	B-cell malignancies	Idelalisib	1
	#NCT03540849	Recruiting	HL	Brentuximab vendotin	2
	#NCT02512497	Recruiting	T-cell leukemia or lymphoma	Romidepsin	1
	#NCT01264315	Active, not recruiting	Multiple myeloma	Lenalidomide	2
	#NCT02440464	Active, not recruiting	Multiple myeloma	Ixazomib	2

	ClinicalTrials.gov identifier	Status	Disease	Maintenance agent	Phase study
FLT3⁺ disease	#NCT02997202	Active, not recruiting	FLT3⁺ AML	Gilteritinib	3
FLT3⁺ disease	#NCT02400255	Active, not recruiting	FLT3⁺ AML	Crenolanib	2
IDH mutated disease	#NCT03515512	Active, not recruiting	AML, MDS, CMML	Enasidenib	1
	#NCT03728335	Recruiting	AML	Enasidenib	1
	#NCT04522895	Recruiting	AML, MDS, CMML	Enasidenib	2
	#NCT04522895	Recruiting	AML, MDS	Enasidenib, ivosidenib	3
	#NCT03564821	Recruiting	AML, MDS, CMML	Ivosidenib	1
Ph⁺ disease	#NCT05024357	Recruiting	Ph⁺ ALL	Dasatinib	NA
HMA-based approaches	#NCT04173533	Recruiting	AML, MDS	Azacitidine	3
	#NCT01995578	Active, not recruiting	AML, MDS	Azacitidine	2
	#NCT03931291	Active, not recruiting	AML, MDS	Azacitidine, APR-246	2
	#NCT02124174	Recruiting	AML, MDS	Azacitidine, valproic acid	2
	#NCT03613532	Recruiting	AML, MDS	Azacitidine, venetoclax	1
	#NCT04161885	Recruiting	AML	Azacitidine, venetoclax	3
	#NCT04980404	Recruiting	MDS, CMML	Decitabine/cedazuridine	1
Additional targeted or disease-specific approaches	#NCT04674345	Recruiting	Acute leukemia	Sorafenib	2
	#NCT04168502	Recruiting	AML	Glasdegib	3
	#NCT03932643	Recruiting	AML, MDS	ONC 201	1
	#NCT03286530	Recruiting	AML, MDS	Ruxolitinib	2
	#NCT03267186	Active, not recruiting	Acute leukemia, CML	Ibrutinib	2
	#NCT04326764	Recruiting	AML, MDS	Panobinostat	3
	#NCT01433965	Active, not recruiting	AML, MDS	Lenalidomide	1
	#NCT02807883	Active, not recruiting	ALL	Blinatumomab	2
	#NCT03114865	Recruiting	B-cell ALL or NHL	Blinatumomab	1B/2
	#NCT03151057	Active, not recruiting	B-cell malignancies	Idelalisib	1
	#NCT03540849	Recruiting	HL	Brentuximab vendotin	2
	#NCT02512497	Recruiting	T-cell leukemia or lymphoma	Romidepsin	1
	#NCT01264315	Active, not recruiting	Multiple myeloma	Lenalidomide	2
	#NCT02440464	Active, not recruiting	Multiple myeloma	Ixazomib	2

Accessed on 25 October 2021 with search terms “maintenance allogeneic transplant,” “maintenance allo,” or “maintenance post transplant.” HL, Hodgkin lymphoma; NA, not applicable; NHL, non-Hodgkin lymphoma.

View Large

This Feature Is Available To Subscribers Only